New Drug Evaluation: lesinurad tablet, oral
|
|
- Tiffany Park
- 5 years ago
- Views:
Transcription
1 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon Phone Fax New Drug Evaluation: lesinurad tablet, oral Date of Review: May 2016 End Date of Literature Search: April 2016 Generic Name: lesinurad Brand Name (Manufacturer): Zurampic (AstraZeneca) PDL Class: Gout AMCP Dossier Received: Yes Research Questions: What are the differences in efficacy between lesinurad and other antigout agents at reducing acute attacks of gout, either when treated alone or concomitantly with another anti-gout agent? What are the differences in harms between lesinurad and other antigout agents when used to prevent acute attacks of gout? Are there any subpopulations based on demographics (age, race, gender, etc.) or comorbid conditions or concomitant drugs that lesinurad has demonstrated greater efficacy/effectiveness or less harm than other anti-gout agents? Conclusions: There is insufficient comparative evidence from 3 unpublished trials that lesinurad is superior to existing antigout agents when used in combination with allopurinol or febuxostat. There is low quality evidence that the use of lesinurad 200 mg and 400 mg once daily in combination with at least 300 mg of allopurinol daily demonstrates a statistically significant higher proportion of patients able to reduce serum uric acid <6mg/dL versus placebo over 6 months [Les200+allo: RR 0.26 (95% CI, 0.17 to 0.36), p=< and RR 0.32 (95% CI, 0.23 to 0.41), p=<0.0001; Les400+allo: RR 0.31 (95% CI, 0.22 to 0.41) P=< and RR 0.43 (95% CI,0.34 to 0.52), P=<0.001], and is able to achieve statistically significant mean reductions (mg/dl) in serum uric acid levels versus placebo over 6 months [Les200+allo: -1.00; 95% CI to -0.66, p <0.001, Les400+allo: -1.23; 95% CI to -0.89, p <0.001]; however, the clinical significance of this reduction is unknown. There is low quality evidence that the use of lesinurad once daily in combination with febuxostat 80 mg daily demonstrates a statistically significant higher proportion of patients able to reduce serum uric acid <5mg/dL versus placebo over 6 months in lesinurad 400 mg [RR 0.29 (95% CI, 0.17 to 0.42); p<0.0001] but not in lesinurad 200 mg [RR 0.10 (95% CI, to 0.23), p= Lesinurad did show statistically significant reductions in serum uric acid levels versus placebo over 6 months [Les200+FBX ( % CI to -0.30, p =0.002) and Les400+FBX ( % CI to -1.40, p <0.001)]; the clinical significance of this reduction is unknown. There is insufficient evidence that lesinurad in combination with a xanthine oxidase inhibitor demonstrates efficacy in reduction of gout flares, provides symptom relief, results in function improvement, or improves health-related quality of life. There is moderate quality evidence that lesinurad treatment is associated with an increased risk of renal adverse events, including reversible and nonreversible creatinine elevations and serious renal-related adverse events such as acute renal failure. There is insufficient evidence that any subgroups may benefit from lesinurad more than the general population for which it has been studied. All patients studied were adults, mostly white males with an age range 21 to 82.
2 Recommendations: Due to limited evidence of improvement in clinically relevant outcomes and unknown long term safety risks, maintain Zurampic as non-preferred on PMPDP until demonstration of benefit over existing preferred agents in this class is established. Background: Gout is an inflammatory arthritic disease initiated by monosodium urate (MSU) crystal deposition in joints and connective tissue tophi which often lead to significant pain and disability. 1,2,3,4 Gout affects 3.9% of the adult US population but is most prevalent in middle-aged men and post-menopausal women. 3 Chronic hyperuricemia stems from physiologic disturbances of urate metabolism and clearance which is the most important risk factor for the development of gout. 1,2,3 Other risk factors for the development of gout in men include obesity, weight gain, hypertension, use of diuretic agents, and alcohol. 1,2,4 Accumulation of excessive serum uric acid (SUA) may also result in a range of destructive renal complications such as urolithiasis, chronic urate nephropathy, and acute renal failure. 1,2,4 The goals of gout treatment are to alleviate the pain and inflammation of acute gout attacks and to prevent gout flares and uric acid (UA) crystal deposition. 1,2 The American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) guidelines recommend SUA levels < 6 mg/dl (or = 6 mg/dl, EULAR) in patients with gout. 1,2,5,6 Although most patients with elevations in uric acid will not develop gout, if left untreated, progression towards gout generally follows 4 stages: asymptomatic hyperuricemia, acute gout, interval gout, and chronic tophaceous gout. Pharmacologic therapy for gout is typically initiated for acute attack. 7 Non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, or corticosteroids have been used to control the symptoms of acute gout. NSAIDs and colchicine are commonly used to relieve associated inflammation and pain but do not affect urate excretion or metabolism. 7,8,9 Corticosteroids such as the oral glucocorticoid prednisone are used as an alternative to NSAIDs or colchicine in patients with renal impairment or risk of hemorrhage. 7,8,9 The management of chronic gout is largely based upon effective control of SUA concentrations. 7,8,9 Elevated serum urate levels (>7 mg/dl in men; >6 mg/dl in women) are related to purine metabolism defects, under-excretion of uric acid, amplified nucleic acid turnover, or hyper-synthesis of purine. 1,2 Three main pharmacologic mechanisms are targeted for gout treatment: management of hyperuricemia through reduction of uric acid production, increased urate secretion through reabsorption inhibition, or by enhanced enzymatic breakdown of uric acid. 7,8,9 Xanthine oxidase inhibitors (XOIs) such as allopurinol and febuxostat represent the mainstay of chronic gout therapy. 7,8,9 XOIs are utilized to manage overproduction and/or underexcretion of urate and by the inhibition of xanthine to uric acid conversion. 7,8,9 Probenecid, a second-line uricosuric agent, inhibits uriate transporters (URAT) in the proximal renal tubules to prevent UA reabsorption and accelerate uric acid excretion. 9 Other agents such as pegloticase and rasburicase are recombinant enzymatic proteins used to catalyze the oxidation of urate to allantoin. 9,10 These enzymes are typically reserved for individuals unresponsive or intolerant to XOIs or uricosuric therapy. 9,10 Lesinurad (Zurampic ) is a new agent proposed to increase excretion of UA through inhibition of URAT1 transport proteins in a mechanism similar to probenecid. 9,10
3 See Appendix 1 for Highlights of Prescribing Information from the manufacturer, including Black Boxed Warning and Risk Evaluation Mitigation Strategies (if applicable), indications, dosage and administration, formulations, contraindications, warnings and precautions, adverse reactions, drug interactions and use in specific populations. Clinical Efficacy: Approval for lesinurad was based on 3 unpublished Phase III, double-blind, randomized, placebo-controlled clinical trials (Studies 301, 302, and 304) 11 that compared lesinurad plus a background xanthine oxidase inhibiting (XOI) agent to active placebo plus a XOI over 12 months. Study 303 investigated the efficacy and safety of lesinurad monotherapy but were later dropped by the manufacturer for renal safety concerns. 11 The effectiveness of lesinurad was evaluated based on the proportion of gout patients who achieved goal a pre-defined serum uric acid reduction at month All studies were conducted in adults between years with inadequate hypouricemic response to a stable dose of a XOI. Patients were instructed to take lesinurad at the same time each day in the morning with their XOI. For gout flare prophylaxis, patients received colchicine or NSAIDs +/- proton pump inhibitor through month 5 in each of the studies. Patients with significant cardiac disease (unstable angina, myocardial infarction, stroke, DVT, uncontrolled hypertension during screening, etc) or hepatic disease were excluded. Concomitant use of urate lowering medications besides allopurinol, immunomodulating agents, salicylates, or epoxide hydrolase inhibitors were prohibited. Agents with secondary uricosuric effects were not permitted. At the conclusion of the 12-month study period for each trial, patients had a 14-day follow-up. 11 Study 301 was a US-based, multicenter trial (n=603) that assessed the clinical benefits, safety and serum urate-lowering ability of lesinurad plus allopurinol versus placebo plus allopurinol. 11 Patients successfully screened during the initial 28-day period were randomized 1:1:1 by renal function (60 ml/min cutoff) and presence of tophi to one of the following treatment groups: Placebo plus allopurinol daily (P+allo), lesinurad 200 mg plus allopurinol daily (Les200+allo), or lesinurad 400 mg plus allopurinol daily (Les400+allo). All subjects had received 300 mg/day of allopurinol unless renal impairment (estcrcl > ml/min) necessitated dose reduction to 200 mg/day. The primary endpoint measured was the proportion of patients with a sua level <6.0 mg/dl at Month 6. A greater proportion of patients treated with Les200+allo and Les400+allo demonstrated a modest statistically significant response to therapy compared to P+allo (RR 0.26 (95% CI, 0.17 to 0.36), p=< and RR 0.31 (95% CI, 0.22 to 0.41), P=<0.0001, respectively). There was no clear evidence of a dose response difference between les200+allo and les400+allo. The mean change in serum acid (mg/dl) from baseline to month 6 was statistically significant for Les200+allo ( % CI to -0.66, p <0.001) and Les400+allo ( % CI to -0.89, p <0.001). A secondary endpoint which assessed proportion of subjects requiring treatment for a gout flare during the time period from Month 6 to Month 12 was not met for either Les200+allo (P=0.98) or Les400+allo (P=0.61). Another secondary endpoint which was not met for this trial had assessed the proportion of subjects with > 1 target tophus at baseline who experienced complete resolution of at least 1 target tophus by Month 12. The results actually favored placebo for les200+allo [RR: -0.29(95% CI, to -0.08) p=0.02] and were not significant for les400+allo (P=0.60). There were multiple secondary efficacy variables for patient reported outcomes regarding disease activity, pain, and functioning (see section on comparative clinical efficacy for complete listing), however, these findings were not considered statistically significant due to the hierarchical testing method used for multiple endpoints. 11 Study 302 was a 12-month trial (n=610) which had an identical study design to Study 301 but also included US and multinational sites. 11 The primary endpoint for this trial was also met as the proportion of patients achieving target sua level<6.0 mg/dl by month 6 was higher in both Les200+allo and Les400+allo versus P+allo ([RR 0.32 (95% CI, 0.23 to 0.41), p=<0.0001] and [RR 0.43 (95% CI, 0.34 to 0.52), P=<0.001] respectively). Unlike trial 301, a dose-response effect between the two lesinurad groups plus allopurinol was observed. The mean change in serum acid (mg/dl) from baseline to month 6 was statistically significant for Les200+allo ( % CI to -0.75, p <0.001) and Les400+allo ( % CI to -1.03, p <0.001). A secondary endpoint which assessed proportion of
4 subjects requiring treatment for a gout flare during the time period from Month 6 to Month 12 was not met for either Les200+allo (P=0.57) or Les400+allo (P=0.75). As in trial 301, the secondary endpoint for the proportion of subjects with complete resolution of at least 1 target tophus by Month 12 were not significant for either study drug [les200+allo, P=0.85] and les400+allo (P=0.63). Secondary patient reported outcome assessments were also not considered statistically significant due to the hierarchical testing method used for multiple endpoints. 11 Study 304 was a 12-month multinational study (n=324) of adults with tophaceous gout of patients with or without inadequate hypouricemic response to allopurinol or febuxostat. 11 The major inclusion/exclusion criteria was the same as study 301 and 302, but eligible patients had to meet additional inclusion criteria of >1 tophus and a serum uric acid level of >8 mg/dl for those who were not on urate lowering therapy (ULT) (or >6 for those on ULT). Successfully screened patients were randomized into one of 3 groups: placebo plus febuxostat 80 mg daily (P+FBX), lesinurad 200 mg plus febuxostat 80 mg daily (Les200+FBX), or lesinurad 400 mg plus febuxostat 80 mg daily (Les400+FBX). The primary endpoint which evaluated the proportion of patients with sua <5 mg/dl by month 6 was not met in this study for Les200+FBX compared to P+FBX [RR 0.10 (95% CI, to 0.23), p=0.1298], but was statistically significant for Les400+FBX versus P+FBX [RR 0.29 (95% CI, 0.17 to 0.42); p<0.0001]. The mean change in serum acid (mg/dl) from baseline to month 6 was statistically significant for Les200+FBX ( % CI to -0.30, p =0.002) and Les400+FBX ( % CI to -1.40, p <0.001). As in trial 301 and 302, there was no significant clinical benefit for lesinurad + febuxostat in decreased gout flares or demonstration of tophi size reduction or resolution the resolution with either the 200 mg or400 mg lesinurad treatment groups in study 304. Additional secondary efficacy variables were generally not supportive of a beneficial response of lesinurad due to the hierarchical testing used for multiple endpoints and inappropriate use of unadjusted p-values. 11 Clinical Safety: The safety population evaluated all subjects who received at least one dose of the randomized study medication. 11 The safety review for lesinurad plus XOI noted concerns of higher rates of death, major adverse cardiac events (MACE) rates, serious adverse events, and rates of serious and non-serious renal adverse events. 11 Overall, adverse events leading to discontinuation occurred in 9.4%, 6.3%, and 5.4% of the lesinurad 400 mg, lesinurad 200 mg, and placebo group, respectively. 11 Overlapping confidence intervals and the presence of underlying concomitant medical conditions presented a challenge to establish safety conclusions for lesinurad as the exposure-adjusted incidence of death rates for lesinurad appeared low overall. The incidence of MACE events were comparably low in the lesinurad 200 mg + XOI groups, but almost doubled for the lesinurad 400 mg + XOI groups with the majority of increased events attributed to nonfatal MI. 11 Blood pressure, cholesterol, and electrocardiac findings appeared to be unaffected by lesinurad. 11 Again, the small numbers of events and overlapping confidence intervals presented difficulty for conclusions to be made about lesinurad and MACE events. 11 Table 1: Incidence of Adjudicated MACE Events (Studies 301, 302, and 304). 11 Lesinurad 400 mg + XOI Lesinurad 200 mg + XOI Placebo + XOI (n=516) (n=510) (n=511) Number patients with adjudicated CV events MACE CV Death Nonfatal MI Nonfatal stroke 0 0 3
5 The number of serious adverse events were reported to be highest under the Metabolism and Nutritional Disorder System Organ Class but with pooled data the incidence was still 1% for both doses of lesinurad + XOI. 11 The increased risk of adverse renal events was highest with lesinurad 400 mg while lesinurad 200 mg + XOI appeared to be more similar to placebo + XOI. 11 Increased blood creatinine was the most common adverse event leading to discontinuation in 1.8%, 0.8%, and 0.8% of the lesinurad 400 mg, lesinurad 200 mg, and placebo groups, respectively. 11 A black box warning identifies risk of acute renal failure when lesinurad is given without concomitant XOI therapy. 12 The overall summary of renal events are listed in the table below. Table 2: Incidence of Renal-related Adverse Events in Studies 301, 302, and Lesinurad 400 mg + XOI (n=510) Lesinurad 200 mg + XOI (n=511) Placebo + XOI (n=516) Blood creatinine increased 11.8% 5.7% 4.5% Blood urea increased 7.8% 4.3% 2.3% Renal failure 1.2% 0.8% 1.2% Renal failure, acute 0.8% 0.0% 0.4% Nephrolithiasis 2.2% 0.6% 1.7% Other common adverse events were upper respiratory tract infection, hypertension, headache, and influenza. 11 Table 3 Common Adverse Events in Studies 301, 302, and Preferred Term Placebo + XOI (n=516) Lesinurad 400 mg + XOI (n=510) Lesinurad 200 mg + XOI (n=511) Total Lesinurad + XOI (n=1021) Upper respiratory tract 44 (8.5%) 57 (11.2%) 46 (9.0%) 103 (10.1%) infection Hypertension 25 (4.8%) 35 (6.9%) 31 (6.1%) 66 (6.5%) Headache 21 (4.1%) 30 (5.9%) 27 (5.3%) 57 (5.6%) Influenza 14 (2.7%) 16 (3.1%) 26 (5.1%) 42 (4.1%) Look-alike / Sound-alike Error Risk Potential: FDA deemed Zurampic acceptable from both a promotional and safety perspective. 11
6 Pharmacology and Pharmacokinetic Properties: 12 Parameter Selective uric acid reabsorption inhibitor (SURI) that reduces the function of the URAT1 and OAT4 transporter proteins Mechanism of Action involved in renal urate reabsorption Absorption Rapid, almost 100 % bioavailability; maximum plasma concentrations (Cmax) attained within 1 to 4 hours. Distribution and Protein Binding Vd is 20 L; >98% is bound to albumin Metabolism Oxidative metabolism mainly via CYP2C9 Half-Life Approximately 5 hours Elimination Total clearance is approximately 6 L/hr. Urine (63%; roughly 30% as unchanged drug); feces (32%). Abbreviations: URAT = urate transporter 1; OAT = organic anion transporter; Comparative Clinical Efficacy: Clinically Relevant Endpoints: 1) Incidence of gout flares 2) Symptom relief 3) Function improvement 4) Health-related quality of life Primary Study Endpoint: 1. Proportion of patients achieving a target serum Uric Acid level <6.0 mg/dl at Month 6 (Studies 301 & 302) or < 5 mg/dl by month 6 (Study 304) 2. Mean change in serum acid (mg/dl) from baseline to month 6 Secondary Study Endpoints: 1. Mean rate of gout flares requiring treatment between Months 6 and 12; 2. Proportion of patients with 1 target tophus at baseline who experienced complete resolution of at least 1 target tophus by Month Mean percent change from baseline in the sum of the areas for all target tophi at each visit 4. Proportion of subjects with improvement from baseline in diseaserelated disability as measured by self-reported questionnaires: (HAQ-DI, SF-36, TSQM, SDS, PGA) 5. Proportion of subjects whose sua level is <6.0 mg/dl, <5.0 mg/dl and <4.0 mg/dl at each visit 6. Absolute and percent change from baseline in sua levels at each visit 7. Proportion of subjects requiring treatment for a gout flare at monthly intervals between Month 6 and Month 12
7 Ref./ Study Design Study 301 Phase III, R,DB,PC, MC Comparative Evidence Table Drug Regimens/ Duration 1. lesinurad 200 mg + allopurinol once daily (Les200+A) 2. lesinurad 400 mg + allopurinol once daily (Les400+A) 3. Placebo + allopurinol once daily (P+A) Patient Population N Efficacy Endpoints ARR/NN T Demographics: Mean Age 52 (22-81) yr Male 94%; Female 6% White 76% Black/African American 15% Asian 4% BMI (mean) 35 Mean baseline sua level (mg/dl) 6.94 (+1.27) Mean# gout flares 12 mo. prior: 5 (+3.6) Duration since gout dx (yrs): 12 (+9) Mean # tophi at baseline: 1.9 (+1.3) Renal function w/ EstCrCl >60: 79% EstCrCl <60: 21% >1 comorbid condition (HTN, Hyper-L, Hyper- TG, DM, Kidney stones) 82% Key Inclusion Criteria: M/F years Gout Taking allopurinol as sole urate-lowering tx for 8 weeks prior to screening Able to take colchicine or an NSAID sua level > 6.5 mg/dl at the screening visit and Day 7 >2 gout flares in the prior 12 months Key Exclusion Criteria: Unresolved gout flare >7 d prior to baseline ITT PP Attrition: (30%) (30%) (26%) Primary Endpoint: Proportion of patients with a sua level <6.0 mg/dl at Month % 2. 59% 3. 28% Treatment difference: 1 vs 3: RR 0.26 (95% CI, 0.17 to 0.36), p=< vs 3: RR 0.31 (95% CI,0.22 to 0.41) P=< Mean change in serum acid (mg/dl) from baseline to month 6: 1 vs 3: -1.00; 95% CI to , p < vs 3: -1.23; 95% CI to , p <0.001 Secondary Endpoints: Mean rate of gout flares requiring tx months 6-12: 1 vs 3: RR 0.99(95% CI, 0.61 to 1.61) p= vs 3: RR 0.88(95% CI, 0.54 to 1.43) p=0.61 Proportion of patients with complete resolution of 1 target tophus by Month 12 (in patients with target tophi at baseline): 1 vs 3 ARR 26/NNT 4 ARR 31/NNT 4 Safety Outcomes ARR/NNH Risk of Bias/ Applicability Major Adverse Cardiovascular Events CV death, non-fatal MI, nonfatal stroke (pooled data from studies 301 and 302): 1. RR 0.61 (95% CI, 0.15 to 2.43) 2. RR 1.85 (95% CI, 0.83 to 4.11) 3. RR 0.60 (95% CI, 0.15 to 2.41) p-value not given Any Renal AEs: (5%) (12%) (4%) Blood Creatinine Elevation (4%) (8%) 3. 9 (2%) N/A Risk of Bias (low/high/unclear): Selection Bias: (Unclear) No details on randomization procedure or attempts to conceal allocation methods; age distribution around mean undisclosed; similar baseline demographics Performance Bias: (Unclear) Extensive screening with a run-in period; few to no details on methods of patient or provider blinding Detection Bias: (Unclear) No details provided on outcome assessment blinding; investigator determined medically appropriate dose based on renal function; no details whether data analysts were blinded Attrition Bias: (Unclear) higher rates of early discontinuation from study medication treatment in the two lesinurad + ALLO groups Reporting Bias: (Unclear) Unpublished study Applicability: Patient: Extensive inclusion and exclusion criteria; disproportionate participation of obese white males; baseline level of disability unclear; low Hispanic/Latino enrollment; 98% subjects did not report history of alcoholism Intervention: Only tested in combination with allopurinol Comparator: Higher proportion of patients in PBO group took >300 mg/day of allopurinol compared to lesinurad groups (17% vs 5% or 3%, respectively) Outcomes: Magnitude of drug s effect modest; unclear dose-response relationship; More lesinurad 400 took thiazide/th-type diuretics which may have affected the urinary excretion of UA and possibly outcome; Clinical significance of primary endpoints required assessment of secondary endpoints of gout flares and tophus resolution, however, findings from the major secondary
8 Study 302 Phase III, R, DB, PC, MC 1. lesinurad 200 mg + allopurinol once daily (Les200+A) 2. lesinurad 400 mg + allopurinol once daily (Les400+A) 3. Placebo + allopurinol once daily (P+A) Previous treatment with pegloticase > 14 drinks of alcohol consumed per week UA (NYHA) class III or IV heart failure, MI, stroke or DVT within the last 12 months; or currently receiving anticoagulants Uncontrolled HTN EstCrCl <30 ml/min Elev. GGT, ALT, AST,or CK Active PUD requiring tx H/O xanthinuria, active liver disease, or hepatic dysfunction Demographics: Mean Age 51 yr Male 96%; Female 4% White 79% Black/African Amer 10% Asian 5% BMI (mean) 34 Mean base. sua level (mg/dl): 6.94 (+1.27) Mean# gout flares 12 mo. prior: 5 (+3.6) Duration since gout dx (yrs): 12 (+9) Mean # tophi at baseline: 2.2 (+1.4) Renal function w/ EstCrCl >60: 84% EstCrCl <60: 16% >1 comorbid condition (HTN, Hyper-L, Hyper- TG, DM, Kidney stones) 79% Key Inclusion/Exclusion Criteria: Same major criteria as trial 301 ITT PP Attrition: (21%) (28%) (25%) RR: -0.29(95% CI, to ) p= vs 3: RR -0.08(95% CI, to 0.20) p=0.60 Patient reported outcomes: HAQ-DI Improvement > 0.25 Month 12 1 vs 3: -5%, p= vs 3: -6%, p=0.27 Primary Endpoint: Proportion of patients with a sua level <6.0 mg/dl at Month % 2. 67% 3. 23% Treatment difference: 1 vs 3: RR 0.32 (95% CI, 0.23 to 0.41), p=< vs 3: RR 0.43 (95% CI,0.34 to 0.52), P=<0.001 Mean change in serum acid (mg/dl) from baseline to month 6: 1 vs 3: -1.08; 95% CI to , p < vs 3: -1.36; 95% CI to , p <0.001). Secondary Endpoints: Mean rate of gout flares requiring tx months 6-12 ARR 32/NNT= 4 ARR 43/NNT 3 (Pooled safety data see study 301 table above) N/A endpoints not considered statistically significant due to the hierarchical testing method used for multiple endpoints; safety concerns due to higher rate of deaths, a higher rate of MACE events, a higher rate of serious adverse events and a higher rate of serious and non-serious renal-related adverse events. Setting: Conducted only in United States (100%) Risk of Bias (low/high/unclear): Selection Bias: (Unclear) No details on randomization procedure or attempts to conceal allocation methods; age distribution around mean undisclosed; similar baseline demographics Performance Bias: (Unclear) extensive screening with a run-in; few to no details on methods of patient or provider blinding Detection Bias: (Unclear) No details provided on outcome assessment blinding; investigator determined medically appropriate dose based on renal function; no details whether data analysts were blinded Attrition Bias: (Unclear) no obvious trend but highest in Les400+allo group Reporting Bias: (Unclear) Unpublished study Applicability: Patient: Similar to trial 301 Intervention: Similar to trial 301 Comparator: Placebo; More patients with kidney stones were randomized to the PBO+ Allo group than lesinurad groups (14% vs 11% or 9%, respectively) Outcomes: Dose response effect observed; Clinical significance of primary endpoints required assessment of secondary endpoints
9 1 vs 3: RR 0.88 (95% CI, 0.57 to 1.37) p= vs 3: RR 0.93(95% CI, 0.60 to 1.45) p=0.75 Proportion of patients with complete resolution of 1 target tophus by Month 12 (in patients with target tophi at baseline) that of gout flares and tophus resolution, however, findings from major secondary endpoints not considered statistically significant due to the hierarchical testing method used for multiple endpoints; safety concerns raised included higher rate of deaths, a higher rate of MACE events, a higher rate of serious adverse events and a higher rate of serious and non-serious renalrelated adverse events. Setting: US (51%), Canada, Europe, Australia, New Zealand, South Africa 1 vs 3: RR: (95% CI, to 0.20) p=0.85 (not significant) 2 vs 3: RR -0.06(95% CI, to 0.17) p=0.63 Study 304 Phase III, R, DB, PC, MC 1. lesinurad 200 mg + febuxostat 80 mg once daily (Les200+F) 2. lesinurad 400 mg + febuxostat 80 mg once daily (Les400+F) 3. Placebo + febuxostat once daily (P+F) Demographics: Mean Age 54 yr Male 95%; Female 5% White 80% Black/African Amer 11% Asian 6% BMI (mean) 32 Mean base. sua level (mg/dl): 5.27 (+1.63) Mean# gout flares 12 mo. prior: 7 (+8) Duration since gout dx (yrs): 15 (+11) Mean # tophi at baseline: 1.8 (+1.2) Renal function w/ ITT PP Attrition: (28%) (30%) (24%) HAQ-DI improvement of 0.25, month 12 and difference in proportions HAQ-DI Improvement > 0.25 Month 12 1 vs 3: -10%, p= vs 3: -1%, p=0.82 Primary Endpoint: Proportion of patients with a sua level <5 mg/dl at Month % 2. 76% 3. 47% Treatment difference: 1 vs 3: RR 0.10 (95% CI, to 0.23), p= vs 3: RR 0.29 (95% CI, 0.17 to 0.42); p< Mean change in serum acid (mg/dl) from baseline to NA ARR 29/NNT 4 MACE events CV death, non-fatal MI, non-fatal stroke: 1. RR 2.35 (95% CI, 0.59 to 9.41) 2. RR 2.28 (95% CI, 0.57 to 9.11) 3. RR 1.13 (95% CI, 0.16 to 7.99) p-value not given Any Renal AEs: 1. 9 (9%) (10%) N/A Risk of Bias (low/high/unclear): Selection Bias: (Unclear) No details on randomization procedure or attempts to conceal allocation methods; age distribution around mean undisclosed; similar baseline demographics Performance Bias: (Unclear) blinding process not adequately described Detection Bias: (Unclear) insufficient description for blinding of outcome assessors Attrition Bias: (High) Significant withdrawal rate versus PBO and possible incomplete data Reporting Bias: (Moderate) Most primary and secondary outcomes were not statistically significant
10 EstCrCl >60: 77% EstCrCl <60: 23% >1 comorbid condition (HTN, Hyper-L, Hyper- TG, DM, Kidney stones) 75% Key Inclusion/Exclusion Criteria: Same major criteria as trials 301 and 302 with additional criteria: sua >8 mg/dl for those not on ULT or >6 mg/dl for those on ULT, and >1 tophus on the hands/wrists and/or feet/ankles >5 mm and <20 mm in diameter month 6: 1 vs 3: -0.79; 95% CI to , p =0.002) 2 vs 3: -1.88; 95% CI to , p <0.001 Secondary Endpoints*: Frequency of gout flares: 1 vs 3: RR 1.2 (95% CI, 0.7 to 2.1), p= , Not significant 2 vs 3: RR 0.5 (95% CI, 0.3 to 1.0); p= Complete resolution of at least 1 target tophus by month 12: 1 vs 3: RR: 0.04 (95% CI, to 0.16), p=0.45 Not significant 2 vs 3: RR: 0.09 (95% CI,-0.02 to 0.21); p=0.12 Not significant 3. 6 (6%) Blood Creatinine Elevation 1. 9 (9%) (10%) 3. 6 (6%) Applicability: Patient: Extensive inclusion/exclusion study participant requirements, difficult to apply to OHP population Intervention: concomitant XOI for all groups; compliance rate difficult to assess Comparator: PBO; Difficult to assess true magnitude of lesinurad contribution since combined with febuxostat Outcomes: Clinical significance of primary endpoints required assessment of secondary endpoints of gout flares and tophus resolution, however, findings from major secondary endpoints not considered statistically significant due to the hierarchical testing method used for multiple endpoints; safety concerns raised included higher rate of deaths, a higher rate of MACE events, a higher rate of serious adverse events and a higher rate of serious and non-serious renalrelated adverse events. Setting: US (75%), Canada, Europe, Australia, New Zealand Complete or partial resolution of at least 1 target tophus by month 12: 1 vs 3: RR 0.06 (95% CI, to 0.21), p=0.45 Not significant 2 vs 3: RR 0.08 (95% CI,-0.07 to 0.23) P=0.12, Not significant HAQ-DI improvement of 0.25, month 12 and difference in proportions HAQ-DI Improvement > 0.25 Month 12 1 vs 3: -8%, p= vs 3: -19%, p=0.02
11 Abbreviations: AE=adverse event; ALT=alanine aminotransferase, ARR = absolute risk reduction; AST=aspartate aminotransferaseorci = confidence interval;ck=creatinine kinase; DB=double blind; EstCrCl = estimated Creatinine Clearance; GGT=gamma-glutamyltransferase; HAQ-DI=Health Assessment Questionnaire Disability Index; ITT = intention to treat; MC=multicenter; mitt = modified intention to treat; N = number of subjects; NA = not applicable; NNH = number needed to harm; NNT = number needed to treat; NSAID=non-steroidal anti inflammatory drug; NYHA=New York Heart Association;PBO=placebo; PC=placebo controlled; PP = per protocol. PUD=peptic ulcer disease;r=randomized; SUA = serum uric acid; XOI=xanthine oxidase inhibitor;
12 References: 1. Khanna D, Fitzgerald JD, Khanna PP, et al American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care & Research. 2012;64(10): doi: /acr Khanna D, Khanna PP, Fitzgerald JD, et al American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care & Research. 2012;64(10): doi: /acr Diagnosis of Gout - Research Review - Final AHRQ Effective Health Care Program. Accessed April 7, Diagnosis, Treatment, and Prevention of Gout - American Family Physician. Accessed April 7, Zhang W. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Annals of the Rheumatic Diseases. 2006;65(10): doi: /ard Zhang W. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases. 2006;65(10): doi: /ard Management of Gout - Research Review - Final AHRQ Effective Health Care Program. Accessed April 7, Sivera F, Andrés M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2): doi: /annrheumdis Diaz-Torne C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. [Review]. Current Opinion in Rheumatology. 2015;27(2): doi: /bor Crittenden DB, Pillinger MH. New Therapies for Gout. Annual Review of Medicine. 2013;64(1): doi: /annurev-med Lesinurad Summary Review. US Food and Drug Administration Center for Drug Evaluation and Research. Accessed April 7, Zurampic (lesinurad) [prescribing information] Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2015.
13 Appendix 1: Highlights of Prescribing Information
New Drug Evaluation: lesinurad tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout
Lesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout Briefing Document for the Arthritis Advisory Committee Meeting Date: 23 October 215 Ardea
More informationUrate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout
Philippine Journal of Internal Medicine Meta-Analysis Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Erika Bianca S. Villazor-Isidro, M.D.*; John Carlo G.
More informationZurampic. (lesinurad) New Product Slideshow
Zurampic (lesinurad) New Product Slideshow Introduction Brand name: Zurampic Generic name: Lesinurad Pharmacological class: URAT1 inhibitor Strength and Formulation: 200mg; tablets Manufacturer: Ironwood
More informationCost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout
Cost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout The NCPE has issued a recommendation regarding the cost-effectiveness of Lesinurad (Zurampic ) in combination with
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other PEGLOTICASE KRYSTEXXA 37154 GUIDELINES FOR USE 1. Does the patient have a diagnosis of symptomatic chronic gout (prior to initiating Krystexxa therapy) with clinical
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD for the CARES Investigators Calhoun Cardiology Center University
More informationLiterature Scan: Analgesics for Gout. Month/Year of Review: April 2015 Date of Last Review: January 2014
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503 947 1119 Copyright 2012 Oregon State University. All Rights
More informationUloric Step Therapy Program
Uloric Step Therapy Program Policy Number: 5.01.584 Last Review: 7/2017 Origination: 7/2014 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for brand
More informationGout 2.0. Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy
Gout 2.0 Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy Case 48 year old man presents with swollen, painful left toe that started overnight. Didn t hurt when he went to bed. No
More informationOBJECTIVES GOUT GOUTY INFLAMMATION 6/10/2016 GOUT INCIDENCE AND PREVALENCE MONOSODIUM URATE CRYSTAL DEPOSITION DISEASE
GOUT Lisa Talbert, MD Family Medicine Update June 15, 2016 OBJECTIVES To be familiar with the clinical presentation and pathophysiology of gouty arthritis Be able to incorporate current guidelines when
More informationN Engl J Med 2018;378: DOI: /NEJMoa Lin, Wan-Ting 2018/06/27
N Engl J Med 2018;378:1200-10. DOI: 10.1056/NEJMoa1710895 Lin, Wan-Ting 2018/06/27 1 Introduction Gout is a chronic illness characterized by hyperuricemia, arthropathy, tophus development, and urolithiasis
More informationCase presentation. serum uric acid = 11.5 mg/dl 24-hour uric acid excretion = 300 mg
GOUT 55 y/o male 12 hours pain in my big toe & ankle went to bed last night feeling fine felt as if had broken toe this morning similar problems in right ankle & left wrist Case presentation lab studies
More informationAchieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP
Achieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP Dr. Paul Doghramji is attending physician at the Pottstown Memorial Medical Center and medical director of Health Services
More informationGout: Update in therapeutics
Summary Gout: Update in therapeutics 29/11/14 Caroline van Durme CHU de Liège Maastricht University Medical Centre+ Why treating gout? Guidelines: ACR 12 Drugs: Colchicine Allopurinol: what about the kidney?
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD, for the CARES Investigators Calhoun Cardiology Center University
More informationZurampic, Duzallo (lesinurad Products)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationClass Update: Drugs for Gout
Copyright 2012 Oregon State University. ll Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLimitations of Use: (1) Duzallo is not recommended for the treatment of asymptomatic hyperuricemia.
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.63 Subject: Duzallo Page: 1 of 5 Last Review Date: December 8, 2017 Duzallo Description Duzallo (lesinurad
More informationZURAMPIC (lesinurad) oral tablet
ZURAMPIC (lesinurad) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 24 June 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 24 June 2009 ADENURIC 80 mg, film-coated tablets B/28 (CIP code: 385 724-4) B/84 (CIP code: 572 820-3) ADENURIC 120
More informationGout Hanan Abdel Rehim
Review article 35 Gout Hanan Abdel Rehim Department of Internal Medicine, Kasr-Al Aini School of Medicine, Cairo University, Cairo, Egypt Correspondence to Hanan Abdel Rehim, MD, 11 Ismaiel Wahby Street,
More informationDrugs Used to Treat Gout. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used to Treat Gout Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Gout is a metabolic disease characterized by recurrent episodes of acute arthritis
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationNovel uricosurics RHEUMATOLOGY. Thomas Bardin 1,2 and Pascal Richette 1,2. Abstract. Introduction REVIEW
RHEUMATOLOGY Rheumatology 2018;57:i42 i46 doi:10.1093/rheumatology/kex433 Novel uricosurics Thomas Bardin 1,2 and Pascal Richette 1,2 REVIEW Abstract Objective. According to recent guidelines, the mainstay
More informationGout A rapid review. Jeremy Jones
Gout A rapid review Jeremy Jones The Hyperuricemia Cascade Dietary purines Tissue nucleic acids Urate Endogenous purine synthesis Overproduction Hyperuricemia Underexcretion Silent tissue deposition Gout
More informationZURAMPIC (lesinurad) tablets, for oral use Initial U.S. Approval: 2015
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZURAMPIC safely and effectively. See full prescribing information for ZURAMPIC. ZURAMPIC (lesinurad)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Krystexxa) Reference Number: CP.PHAR.115 Effective Date: 06.01.13 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationSubject: Krystexxa (pegloticase) Original Effective Date: 06/26/13. Policy Number: MCP-138. Revision Date(s):
Subject: Krystexxa (pegloticase) Original Effective Date: 06/26/13 Policy Number: MCP-138 Revision Date(s): Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 DISCLAIMER This Molina Clinical Policy (MCP) is
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Krystexxa) Reference Number: CP.CPA.57 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationKrystexxa (pegloticase) Document Number: IC-0158
Krystexxa (pegloticase) Document Number: IC-0158 Last Review Date: 06/27/2017 Date of Origin: 02/07/20103 Dates Reviewed: 11/2013, 08/2014, 07/2015, 07/2016, 09/2016, 12/2016, 03/2017, 06/2017 I. Length
More informationGout -revisited. Shrenik Shah
Gout -revisited Shrenik Shah definition Monosodium urate (MSU) crystal deposition episodic and later persistent joint inflammation and tophi All MSU crystal deposition- broader definition EULAR- European
More informationGOUT disease spectrum including
GOUT disease spectrum including *hyperuricemia, *recurrent attacks of acute arthritis associated with monosodium urate crystals in leukocytes found in synovial fluid, *deposits of monosodium urate crystals
More informationAn update on the management of gout
An update on the management of gout 8 The management of gout involves treatment of an acute attack, lifestyle modification and urate lowering treatment to achieve a target serum urate level. Recent evidence
More informationLong-term Treatment of Gout: New Opportunities for Improved Outcomes
Long-term Treatment of Gout: New Opportunities for Improved Outcomes Paul P. Doghramji, MD, FAAFP CONTINUING MEDICAL EDUCATION LEARNING OBJECTIVES Make a presumptive diagnosis of gout based on history
More informationNew Drug Evaluation: lixisenatide injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClinical Policy: Colchicine (Colcrys) Reference Number: CP.PMN.123 Effective Date: Last Review Date: 05.18
Clinical Policy: (Colcrys) Reference Number: CP.PMN.123 Effective Date: 05.01.11 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationpegloticase (Krystexxa )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More information1. To review the diagnosis of gout and its differential. 2. To understand the four stages of gout
Objectives 1. To review the diagnosis of gout and its differential GOUT 2. To understand the four stages of gout 3. To develop an approach for the acute treatment of gout Anthony Lim 9/13/12 Cycle 3 4.
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationGout- Treatment Updates. Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA
Gout- Treatment Updates Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA Gout Outline of purine metabolism: (1) amidophosphoribosyltransferase (2) hypoxanthine-guanine phosphoribosyltransferase
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Zurampic) Reference Number: CP.CPA.174 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationGout: Let s Be Crystal Clear. Dr. Philip A. Baer Seacourses Asia CME December 2017
Gout: Let s Be Crystal Clear Dr. Philip A. Baer Seacourses Asia CME December 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or
More informationDrugs for Gout, osteoarthritis and osteoporosis
MMS Pharmacology Lecture 3 Drugs for Gout, osteoarthritis and osteoporosis Dr Sura Al Zoubi Revision Gout The term gout describes a disease spectrum including hyperuricemia, recurrent attacks of acute
More informationRheumatoid arthritis, seronegative spondylarthritides and gout. György Nagy
Rheumatoid arthritis, seronegative spondylarthritides and gout György Nagy Dec 4, 2017 Rheumatoid arthritis Rheumatoid arthritis Chronic, progressive, autoimmune disorder of the joints with extra-articular
More informationGout Treatment Guidelines
Gout Treatment Guidelines Gout is a disorder that manifests as a spectrum of clinical and pathologic features built on a foundation of an excess body burden of uric acid, manifested in part by hyperuricemia,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Lesinurad (Zurampic), Lesinurad/Allopurinol (Duzallo) Reference Number: CP.PMN.150 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial, Medicaid See Important
More informationRheumatology Cases for the Internist
Rheumatology Cases for the Internist Marc C. Hochberg, MD, MPH Professor of Medicine Head, Division of Rheumatology and Clinical Immunology Vice Chair, Department of Medicine University of Maryland School
More informationGOUT. Dr Krishnan Baburaj West herts NHS Trust
GOUT Dr Krishnan Baburaj West herts NHS Trust podagra Gout A disease of kings, the king of diseases History Louis XIV Emperor Augustus Henry VIII Introduction Gout an inflammatory arthritic condition that
More informationPodcast (Video Recorded Lecture Series): Gout for the USMLE Step One Exam. Howard J. Sachs, MD
Podcast (Video Recorded Lecture Series): Gout for the USMLE Step One Exam Howard J. Sachs, MD www.12daysinmarch.com Email: Howard@12daysinmarch.com Podcast (Video Recorded Lecture Series): Gout for the
More informationClinical Policy: Colchicine (Colcrys) Reference Number: CP.PPA.11. Line of Business: Medicaid
Clinical Policy: (Colcrys) Reference Number: CP.PPA.11 Effective Date: 05/11 Last Review Date: 05/176 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationA Patient s Guide to Gout. Foot and Ankle Center of Massachusetts, P.C.
A Patient s Guide to Gout Welcome to Foot and Ankle Center of Massachusetts, where we believe in accelerating your learning curve with educational materials that are clearly written and professionally
More informationMEDICAL POLICY PEGLOTICASE (KRYSTEXXA ) POLICY NUMBER MP POLICY TITLE. Original Issue Date (Created): January 1, 2011
Original Issue Date (Created): January 1, 2011 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY PREAUTHORIZATION REQUIRED Note: Requests for pegloticase
More informationuric acid Non electrolytes of the plasma
73 uric acid Non electrolytes of the plasma 1 Purines and uric acid Fig 2 JFI Uric acid is the major product of catabolism of the purine nucleosides adenosine and guanosine, Uric acid is sparingly soluble
More informationCrystal induced arthropathies. Dr. Amitesh Aggarwal
Crystal induced arthropathies Dr. Amitesh Aggarwal 1 Crystal induced Arthropathies Gout Pseudogout Debilitating illnesses; Recurrent episodes of pain and joint inflammation; Formation and deposition of
More informationClinical Study Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout: Analysis of a Series of Outpatients
Hindawi Publishing Corporation International Journal of Rheumatology Volume 2014, Article ID 263720, 5 pages http://dx.doi.org/10.1155/2014/263720 Clinical Study Allopurinol, Benzbromarone, or a Combination
More informationFebuxostat now subsidised on Special Authority
Gout update: Febuxostat now subsidised on Special Authority 38 Febuxostat was added to the New Zealand Pharmaceutical Schedule on 1 June, 2014. It is now available as a third-line preventive treatment
More informationUpdate on Gout for GPs
Update on Gout for GPs Dr Patrick Kiely PhD FRCP Consultant Physician and Rheumatologist St George s, London 2/3 1/3 Gut bacteria have uricase Chronic erosive arthropathy Clinical spectrum Making the diagnosis
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationLesinurad Combined With Allopurinol
ARTHRITIS & RHEUMATOLOGY Vol. 69, No. 1, January 2017, pp 203 212 DOI 10.1002/art.39840 VC 2016, American College of Rheumatology Lesinurad Combined With Allopurinol A Randomized, Double-Blind, Placebo-Controlled
More informationEssence of the Revised Guideline for the Management of Hyperuricemia and Gout
Research and Reviews Essence of the Revised Guideline for the Management of Hyperuricemia and Gout JMAJ 55(4): 324 329, 2012 Hisashi YAMANAKA,* 1 The Guideline Revising Committee of Japanese Society of
More informationLecture 8 Gout Hinch. Pathogenesis of acute attacks
Gout: disease characterized by deposition of monosodium crystals in soft tissues (cartilage, tendons, bursa) recurrent episodes of acute joint pain & inflammation Pathogenesis of acute attacks Epidemiology:
More informationGout: Develop treatment plan in William Jones, MS, RPh
Gout: Develop treatment plan in 2013 William Jones, MS, RPh (wnjones49@cox.net) Objectives Describe acute gouty arthritis Tx Describe Tx of chronic gouty arthritis. Define the target serum uric acid concentration
More informationLECTURE 5: DRUGS IN GOUT
Red : important Black : in male / female slides Pink : in female s slides only Blue : in male s slides only Green : Dr s notes Grey: Extra information, explanation Editing File LECTURE 5: DRUGS IN GOUT
More informationImplementing AHRQ Effective Health Care Reviews Helping Clinicians Make Better Treatment Choices
Implementing AHRQ Effective Health Care Reviews Helping Clinicians Make Better Treatment Choices Gout: Diagnosis and Management Practice Pointers by MATTHEW R. NOSS, DO, MSEd, U.S. Army Health Clinic,
More informationInitial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment
Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment of Patients in the Midst of an Acute Gout Attack Investor
More informationSchool of Health and Related Research (ScHARR), The University of Sheffield. Produced by
Pegloticase for the treatment of hyperuricaemia in people with symptomatic gout whose disease is refractory to conventional uratelowering therapy, or in whom conventional urate-lowering therapy is contraindicated
More informationProfessional organisation statement template
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationKrystexxa. Krystexxa (pegloticase) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.14 Subject: Krystexxa Page: 1 of 5 Last Review Date: March 16, 2018 Krystexxa Description Krystexxa
More informationNew Drug Evaluation: brivaracetam [tablet and solution, oral; solution, intravenous]
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEfficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
Dalbeth et al. Arthritis Research & Therapy (2019) 21:8 https://doi.org/10.1186/s13075-018-1788-4 RESEARCH ARTICLE Efficacy and safety during extended treatment of lesinurad in combination with febuxostat
More informationD espite reasonable understanding of its pathogenesis
1312 EXTENDED REPORT EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics
More information4/1/2011. New Developments in Gout. Conflict of Interest Declaration. Objectives
New Developments in Gout Tatum N. Mead, Pharm.D. Clinical Assistant Professor UMKC SOP meadt@umkc.edu April 16, 2011 1 Conflict of Interest Declaration I have no actual or potential conflict of interest
More informationCHAPTER:2 GOUT. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:2 GOUT BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY DEFINITION Gout is defined as a peripheral arthritis, resulting from the deposition of MSU crystals
More informationNew Drugs for the Primary Care Provider: What You Need to Know
4:00 4:35 pm New Drugs for the Primary Care Provider: What You Need to Know SPEAKER Gerald W. Smetana, MD Presenter Disclosure Information The following relationships exist related to this presentation:
More informationFebuxostat: a new treatment for hyperuricaemia in gout
Rheumatology 2009;48:ii15 ii19 doi:10.1093/rheumatology/kep088 Febuxostat: a new treatment for hyperuricaemia in gout N. Lawrence Edwards 1 Febuxostat is a new non-purine xanthine oxidase inhibitor that
More informationClinical Biochemistry department/ College of medicine / AL-Mustansiriyah University
Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University Dr. Ali al-bayati NUCLEOTIDE METABOLISM Lec. 3 The salvage pathway of purine synthesis Purines that result from the normal
More informationGOUT IN THE ELDERLY. Learning Objectives. Disclosure. Geriatric Grand Rounds. Geriatric Grand Rounds
Visit web sites: Tuesday, June 2, 2009 12:00 noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this event
More informationJournal of Advanced Scientific Research
Bijoy Kumar Panda et al, J Adv Scient Res, 2012, 3(2): 03-11 3 Journal of Advanced Scientific Research Available online through http://www.sciensage.info/jasr ISSN 0976-9595 Review Article Febuxostat,
More information3/2/2014. Got Gout? Get a Plumber. Objectives. Disclosures
Got Gout? Get a Plumber. Heidi Garcia, PA-C Department of Rheumatology Division of Internal Medicine Mayo Clinic Arizona 2013 MFMER slide-1 Objectives Recall some of the history of Gout. Describe the pathophysiology
More informationGout. Clinical features Most commonly affects middle-aged males. It is an acute and usually relapsing selflimiting
Gout Gout is a syndrome caused by an inflammatory response to the formation of monosodium urate monohydrate crystals which develop secondary to hyperuricemia. Acute and chronic forms are recognized. Hyperuricemia
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationClinical Study Urate Lowering Therapy with Febuxostat in Daily Practice A Multicentre, Open-Label, Prospective Observational Study
International Rheumatology, Article ID 123105, 6 pages http://dx.doi.org/10.1155/2014/123105 Clinical Study Urate Lowering Therapy with Febuxostat in Daily Practice A Multicentre, Open-Label, Prospective
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Gout and Pseudogout Wayne Blount MD Speaker has no disclosures
More informationMethotrexate Injectable Step Therapy Program Summary
Methotrexate Injectable Step Therapy Program Summary This prior authorization applies to Commercial, SourceRx and Health Insurance Marketplace formularies. OBJECTIVE The intent of the methotrexate injectable
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationStudy 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018
Study 2 (1002-047) Pivotal Phase 3 Study Top-Line Results October 29, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationCOMPARATIVE EVALUATION OF EFFICACY AND SAFETY PROFILE OF FEBUXOSTAT WITH ALLOPURINOL IN PATIENTS WITH HYPERURICEMIA AND GOUT
Int. J. Pharm. Med. & Bio. Sc. 2013 P K Agarwal and Bijay Kumar, 2013 Research Paper ISSN 2278 5221 www.ijpmbs.com Vol. 2, No. 4, October 2013 2013 IJPMBS. All Rights Reserved COMPARATIVE EVALUATION OF
More informationOpinion 23 April 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 April 2014 ILARIS 150 mg, powder for solution for injection B/1 vial (CIP: 34 009 397 457-6 3) ILARIS 150 mg, powder
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationRetreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases
Rheumatol Ther (2018) 5:583 594 https://doi.org/10.1007/s40744-018-0111-9 CASE SERIES Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases Allan H. Morton.
More informationEXTENDED REPORT. Clinical and epidemiological research
Handling editor Tore K Kvien Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10. 1136/ annrheumdis- 2016-209213). For numbered affiliations
More informationTherapy for Gout: The Past
Advances in Therapy for Gout: 2011 The Past, Present, and Future Therapy for Gout: The Past May 22, 1997 Pity a Tyrannosaur? Sue Had Gout By MALCOLM W. BROWNE Jonathan Graf, M.D. Associate Professor of
More informationSecondary Gout Associated with Myeloproliferative Diseases* imt. Sinai Hospital
Chapter VI Secondary Gout Associated with Myeloproliferative Diseases* By TS'AI-FAN Yu, M.D. imt. Sinai Hospital In a variety of disorders of hemopoiesis, the turnover of nucleic acids is greatly augmented,
More informationDrug Effectiveness Review Project Summary Report Long acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEnhanced Primary Care Pathway: Gout
Enhanced Primary Care Pathway: Gout 1. Focused summary of gout relevant to primary care Significance: Gout is a chronic, progressive, inflammatory disease requiring appropriate long-term management. Gout
More informationPharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers
Original Manuscript Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers Clinical Pharmacology in Drug Development 2019,
More information